Seres Therapeutics (MCRB) Non-Current Deffered Revenue (2016 - 2024)

Seres Therapeutics has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $95.4 million in Q2 2024.

• Quarterly Non-Current Deffered Revenue changed 0.46% year-over-year to $95.4 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $95.4 million (changed 0.46% YoY) and the FY2023 annual result came in at $95.4 million, up 3.17% from the prior year.
• Non-Current Deffered Revenue held at $95.4 million in Q2 2024 per MCRB's latest filing, from $95.4 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $95.4 million in Q4 2023 and troughed at $1.7 million in Q3 2020.
• A 5-year average of $84.3 million and a median of $89.7 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2020 and 2021: Non-Current Deffered Revenue plunged 98.2% in 2020, then soared 5175.1% in 2021.
• Over 5 years, Non-Current Deffered Revenue stood at $85.6 million in 2020, then rose by 1.67% to $87.0 million in 2021, then climbed by 6.24% to $92.4 million in 2022, then rose by 3.17% to $95.4 million in 2023, then changed by 0.0% to $95.4 million in 2024.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $95.4 million, $95.4 million, and $95.4 million for Q2 2024, Q1 2024, and Q4 2023 respectively.